ANALISIS KEEFEKTIFAN BIAYA LISINOPRIL DENGAN CANDESARTAN DAN KOMBINASI LISINOPRIL-AMLODIPIN DENGAN CANDESARTAN-AMLODIPIN UNTUK TERAPI HIPERTENSI PADA PASIEN DIABETES MELITUS TIPE 2

MUSDALIFAH, SITI (2015) ANALISIS KEEFEKTIFAN BIAYA LISINOPRIL DENGAN CANDESARTAN DAN KOMBINASI LISINOPRIL-AMLODIPIN DENGAN CANDESARTAN-AMLODIPIN UNTUK TERAPI HIPERTENSI PADA PASIEN DIABETES MELITUS TIPE 2. Tesis thesis, Universitas Setia Budi Surakarta.

	Text INTISARI.pdf Download (83kB)
	Text COVER-BAB I.pdf Download (780kB)
	Text BAB II.pdf Restricted to Registered users only Download (445kB) | Request a copy
	Text BAB III.pdf Restricted to Registered users only Download (221kB) | Request a copy
	Text BAB IV.pdf Restricted to Registered users only Download (208kB) | Request a copy
	Text BAB V.pdf Restricted to Registered users only Download (8kB) | Request a copy
	Text BAB VI-LAMPIRAN.pdf Download (5MB)

Abstract

Type 2 diabetes mellitus with hypertension is a diseases requiring high cost to deal with, because of the high cost of drug use and long term treatment. The objective of research was to find out the more cost-effective antihypertension among lisinopril and candesartan, and the combination of lisinoprilamodipin and candesartan amlodipin in the patient with DM type 2 and hypertension. This study was conducted using cross-sectional design in the outpatients with DM type 2 in Local General Hospital of Kudus Regency during July 2013December 2014. The inclusive criteria were as follows: patients with DM type 2 having inpatient treatment, ≥ 18 years old, using lisinopril or candesartan antihypertension and using combination of lisinopril-amodipin and candesartan amlodipin as anti-hypertension. The exclusive criteria were patients with DM type 2 with hypertension who have no complete medical record, were uncontrolled regularly, and have other accompanying diseases. The cost calculated included direct medical cost (hospital perspective) encompassing anti-hypertension, antidiabetic, supplemental drug, laboratory, registration and examination, supporting examination and total therapeutic costs. The effectiveness was expressed in the proportion of patients with blood pressure reaching the target (<140/90 mmHg) within a month of therapy. The statistic analysis was conducted using chi square and t-tests using SPSS for window 11.5. The effectiveness of cost was estimated by comparing ACER and ICER values between lisinopril and candesartan groups, and between combined lisinopril-amlodopin and candesartanamlodipin groups. The result of research on type 2 diabetic patients with hypertension, consisting of 36 samples for lisinopril, 32 for candesartan, 16 for lisinoprilamodipin combination, 16 for candesartan-amlodipin combination, showed that ACER value was IDR 455,400.17 for lisinopril therapy group more cost-effective than IDR 571,332.65 for candesartan therapy group and the ACER value of IDR 567,351.00 for lisinopril-amlodipin therapy group was more effective than IDR 687,577.16 for candesartan-amlodipin therapy group. Keywords: cost effectiveness, type 2 diabetes mellitus with hypertension, lisinopril, candesartan, lisinopril-amlodipin, candesartan-amlodipin.

Item Type:	Thesis (Tesis)
Uncontrolled Keywords:	cost effectiveness, type 2 diabetes mellitus with hypertension, lisinopril, candesartan, lisinopril-amlodipin, candesartan-amlodipin.
Subjects:	H Social Sciences > HJ Public Finance R Medicine > R Medicine (General)
Divisions:	Fakultas Farmasi > Prodi S2 Farmasi
Depositing User:	magdalena kartika ningsih
Date Deposited:	21 Feb 2020 01:25
Last Modified:	21 Feb 2020 01:25
URI:	http://repo.setiabudi.ac.id/id/eprint/2373

Actions (login required)

View Item